This site uses technical cookies, Analytics cookies and third-party cookies for the operation of the site and to improve the user experience.
By clicking on Accept, you consent to the use of cookies. Read the information.

Privacy | Cookie Policy

Faron Pharmaceuticals Oy

https://www.faron.com

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanised antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumours, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalised patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma. Faron is based in Turku, Finland. Further information is available at www.faron.com.
Startup profile
Tech Industry
Biotech
Tags
Biotech, Pharmaceuticals
N. of Employees
10 - 49
Year Enstablishment
2007
Startup Team
Contact person 1
Yes
Name
Yrjo
Surname
Wichmann
Role
V.P., funding
Email
yrjo.wichmann@faron.com
Linkedin profile
Contact person 2
Yes
Name
Alexander
Surname
Spicer
Email
alexander.spicer@faron.com
Linkedin profile
Professional Experience
Business Development and Licensing Director
Investments
Last Round of Investment
Late Stage
Round State
Closed
Year
2021
Amount
15m €
Investors
multiple
Other Round of Investment
Late Stage
Round State
Closed
Year
2015-2020
Amount
+100m €
Investors
multiple
Youtube Video
Categories
Please click on the category to view the subcategories